CONBA(SH:600572)2021-04-23 16:00Financial Performance - The company achieved operating revenue of CNY 1.591 billion in Q1 2021, a decrease of 5.22% year-on-year, but a 16.43% increase compared to Q4 2020[7] - Net profit attributable to shareholders was CNY 47.84 million, down 73.76% year-on-year, while net profit excluding non-recurring gains and losses increased by 4.00% to CNY 121.92 million[7] - Cash flow from operating activities was CNY 160.98 million, a decline of 43.14% year-on-year[7] - The company's financial expenses decreased by 41.00% to RMB 17,224,368.64, attributed to a reduction in financing scale and interest rates[21] - The company's investment income showed a significant decline of 107.22% to RMB -2,560,405.76, mainly due to the previous year’s equity transfer gains[21] - The cash flow from investing activities was RMB -14,542,008.52, a decrease of 116.20% compared to the previous year[21] Asset and Shareholder Information - The company's total assets decreased by 3.88% to CNY 8.919 billion compared to the end of the previous year[7] - The total number of shareholders at the end of the reporting period is 126,005[15] - The total number of shares held by the top ten shareholders includes Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. with 533,464,040 shares, accounting for 20.00%[15] - After the transfer, Hu Jiqiang holds 133,579,085 shares, which is 5.01% of the total share capital, while Kang En Bei Group holds 216,284,371 shares, or 8.11%[23] - The total shares held by Hu Jiqiang and his concerted parties remain unchanged at 355,622,519 shares, accounting for 13.33% of the total share capital[23] - The company's controlling shareholder remains Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd., holding 20% of the shares[26] - The actual controller continues to be the State-owned Assets Supervision and Administration Commission of the Zhejiang Provincial People's Government[26] Product Sales and Revenue - Self-care product sales reached CNY 818 million, down 10.78% year-on-year, accounting for 51.69% of main business revenue[8] - The sales revenue of the respiratory medication "Jin Di" decreased by CNY 160 million, a drop of 76.22% year-on-year[11] - The core product of Guizhou Bait Pharmaceutical Co., Ltd., Danshen Chuanxiong Injection, was removed from the provincial medical insurance payment list, leading to a loss of CNY 9.22 million in Q1 2021[12] - Excluding the impact of non-recurring gains and losses related to JHBP(CY) and Guizhou Bait, the company's net profit for Q1 2021 would have increased by approximately 22.50% year-on-year[12] Changes in Financial Metrics - The company reported a weighted average return on equity of 0.95%, a decrease of 2.89 percentage points compared to the previous year[7] - Basic and diluted earnings per share were both CNY 0.02, a decrease of 71.43% year-on-year[7] - The total amount of accounts receivable increased by 45.37% to RMB 1,250,153,117.12 due to enhanced collection efforts[19] - The deferred income increased by 48.54% to RMB 146,477,354.07, mainly due to government subsidies related to assets received during the reporting period[19] Government Support and Fair Value Changes - The company received government subsidies amounting to RMB 19,517,645.33 during the reporting period[15] - The fair value change loss from trading financial assets was RMB -119,996,599.70, primarily due to the decline in the closing price of JHBP(CY) shares[15]